Medpage Today on MSN6d
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
Monthly Prescribing Reference2d
Hympavzi Approved for Treatment of Hemophilia A or B
Results showed marstacimab was superior to on-demand factor replacement and was noninferior to prophylactic factor-based therapy. The Food and Drug Administration (FDA) has approved Hympavzi ...
Zacks.com on MSN2d
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...
The American Journal of Managed Care5d
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...
pharmaphorum3d
Pfizer rounds out haemophilia portfolio with FDA approval
The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...
FiercePharma5d
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
hemophilianewstoday5d
FDA approves marstacimab, now Hympavzi, for hemophilia
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
Daily5d
FDA Approves New treatment option for cutting bleeding in Hemophilia A or B
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...
Medscape5d
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.